| 12351591 |
KRas inhibitors |
David Anthony Barda, Jolie Anne Bastian, Kelly Wayne Furness, Deqi Guo, James Robert Henry +16 more |
2025-07-08 |
|
| 11993608 |
Selective estrogen receptor degraders |
Jolie Anne Bastian, Jeffrey Daniel Cohen, Daniel Jon Sall, Jennifer Anne McMahon |
2024-05-28 |
$5,773,536,000 |
| 11634426 |
Selective estrogen receptor degraders |
Jolie Anne Bastian, Jeffrey Daniel Cohen, Daniel Jon Sall, Jennifer Anne McMahon |
2023-04-25 |
$844,176,000 |
| 11117902 |
Selective estrogen receptor degraders |
Jolie Anne Bastian, Jeffrey Daniel Cohen, Daniel Jon Sall, Jennifer Anne McMahon |
2021-09-14 |
$897,128,000 |
| 10759786 |
1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer |
Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen +3 more |
2020-09-01 |
$556,181,000 |
| 10654866 |
Selective estrogen receptor degraders |
Jolie Anne Bastian, Jeffrey Daniel Cohen, Daniel Jon Sall |
2020-05-19 |
$925,988,000 |
| 10227310 |
Ghrelin 0-acyl transferase inhibitors |
Christopher Stanley Galka, Erik James Hembre, Nicholas Allan Honigschmidt, Maria Angeles Martinez-Grau, Gema Ruano Plaza +2 more |
2019-03-12 |
$585,169,000 |
| 10093651 |
Ghrelin O-acyl transferase inhibitors |
Christopher Stanley Galka, Erik James Hembre, Nicholas Allan Honigschmidt, Maria Angeles Martinez-Grau, Gema Ruano Plaza |
2018-10-09 |
$225,974,000 |
| 9872853 |
2,3-dihydro-1H-indole compounds |
Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen +3 more |
2018-01-23 |
$162,614,000 |
